Mental healthcare company Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) is focused on helping people heal by developing and delivering innovative treatments and safe, evidence-based psychedelic-assisted therapies.
On September 22, Numinus Wellness (TSX:NUMI) (OTC:NUMIF) announced the opening of a new clinic in Montreal, which will replace an existing clinic in the downtown area. The new location in the Plateau neighbourhood will be able to treat more people with ketamine and offer a broader range of ketamine-assisted therapy options.
“There is significant research showing ketamine can be highly effective in treating depression, addiction, trauma and anxiety, and other common mental health disorders,” said Jason Lapensee, Numinus (TSX:NUMI) (OTC:NUMIF) SVP of Clinical Operations. “Numinus (TSX:NUMI) (OTC:NUMIF) is taking this evidence into consideration as we continue to expand our clinic network and treatment programs across North America.”
Numinus (TSX:NUMI) (OTC:NUMIF) continues to focus on the safe, evidence-based use of ketamine and traditional therapy. There will be more options for how ketamine is given, such as Spravato, intramuscular injections, lozenges, and nasal sprays. There will also be more choices for how long a treatment lasts and what kind of session it is.
Currently, Numinus (TSX:NUMI) (OTCQX:NUMIF) has a six-week ketamine-assisted therapy program for depression, addiction, trauma, and anxiety. Ketamine will be available as a stand-alone treatment as part of the new services. This will allow clients to add to their previous ketamine-assisted therapy, use it as an emergency antidepressant, or use it with treatment from an outside health provider. This will make it easier for clients to get services because they can meet different needs and budgets.
“Numinus (TSX:NUMI) (OTC:NUMIF) recognizes that people in Montreal can benefit from having more treatment options, including ketamine,” said Numinus (TSX:NUMI) (OTC:NUMIF) Founder and CEO Payton Nyquvest. “Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec, while continuing to expand our clientele and market presence.”
Numinus (TSX:NUMI) (OTCQX:NUMIF) currently runs 13 clinics in Canada and the US, including locations in British Columbia, Ontario, Arizona, and Utah. These clinics offer a wide range of services, from mental health therapy to neurologic care, and help clients get psychedelic-assisted treatment through Canada’s federal Special Access Program.
Numinus Now Provides Ketamine-Assisted Therapy in Toronto
On September 19, Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) reported that its Toronto facility, the Neurology Centre of Toronto (NCT) by Numinus (TSX:NUMI) (OTC:NUMIF), is now providing ketamine-assisted therapy to patients suffering from neurologic diseases.
NCT specializes in illnesses such as epilepsy, concussion, brain injury, and functional neurological disorders, providing a broad spectrum of services such as primary neurologic care and supportive therapies by a team of more than 20 specialists. A psychologist will oversee the new program. It will adhere to Numinus‘ (TSX:NUMI) (OTC:NUMIF) existing protocol for ketamine-assisted therapy, which is already in use at its other locations in Canada and the United States and includes sessions for medical screening, medication administration, and integration therapy. The approach will be tweaked to make it more appropriate for people suffering from neurologic disorders. Following the evaluation of the initial cohort, a group of existing patients were considered candidates, with plans to treat further patients.
NCT is increasing its ability to support applications for other psychedelic-assisted therapies through Health Canada’s Special Access Program (SAP) and ketamine-assisted therapy. The SAP is a federal program that allows patients with the documented need to apply for access to investigational medicinal treatments that are not yet available to the general public, including psychedelic therapies like MDMA and psilocybin. A Montreal Numinus (TSX:NUMI) (OTC:NUMIF) physician has built a successful SAP application to give psilocybin-assisted therapy for depression.
SOURCE Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF)
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Subscribe to us on Youtube
PressReach Disclaimer.
